Industry News
Faster FDA Review Ahead for a Treatment Targeting a Major Cause of Pancreatitis
High Triglycerides & Pancreatitis: FDA Review Update
For people living with very high triglycerides, the threat of a sudden, painful attack of acute pancreatitis is never far away. This month brought encouraging news: the FDA has selected a treatment for severe hypertriglyceridemia for a pilot program designed to speed up its review.
Here's what the announcement means, and what it doesn't mean yet, for patients and families in our community.
What Happened
On October 7, 2026, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) accepted its medicine plozasiran into the FDA's Split Real Time Application Review (STAR) pilot program. The company is preparing to ask the FDA to approve plozasiran for a broader group of patients: adults with severe hypertriglyceridemia (sHTG).
Plozasiran is already approved in the United States, as REDEMPLO®, for a smaller group: adults with familial chylomicronemia syndrome (FCS), a rare genetic condition that is the most severe form of high triglycerides. It is also approved for FCS in the European Union, Canada, China, and Australia.
Why High Triglycerides Matter for Your Pancreas
Triglycerides are a type of fat in the blood. When levels climb very high, they can trigger acute pancreatitis, and the risk grows as triglyceride levels rise.
- Severe hypertriglyceridemia (sHTG) generally means triglyceride levels above 500 mg/dL.
- Familial chylomicronemia syndrome (FCS) is the most extreme form, with levels that typically exceed 880 mg/dL.
For many patients, pancreatitis caused by high triglycerides isn't a one-time event. Attacks can come back again and again, leading to repeat hospital stays and worsening health over time. Today, limited treatment options exist to keep triglycerides consistently below the levels doctors consider safe.
What Is the FDA STAR Program?
The STAR pilot program is designed to shorten FDA review time for new uses of medicines that are already approved. To be accepted, the FDA must see clinical evidence suggesting the drug may offer a substantial improvement over available treatments.
In practical terms:
- The application qualifies for a 6-month Priority Review, instead of the standard 10 months.
- The FDA may aim to act at least a month before that 6-month deadline.
The FDA had previously given plozasiran Breakthrough Therapy designation for severe hypertriglyceridemia, another signal that regulators see a meaningful unmet need.
How Plozasiran Works
Plozasiran is an RNA interference (RNAi) medicine. It lowers the liver's production of a protein called APOC3, which normally slows the body's ability to break down and clear triglycerides. By turning down APOC3, the drug helps lower triglyceride levels. It's given as a self-administered injection under the skin once every three months.
What Happens Next
Arrowhead says it expects to submit its application for severe hypertriglyceridemia to the FDA by the end of 2026, followed by applications in other countries. If submitted on schedule, the faster review timeline means an FDA decision could come within about six months of filing.
Important: Plozasiran is not yet approved for severe hypertriglyceridemia beyond FCS. The FDA's acceptance into the STAR program speeds up the review but does not guarantee approval.
What This Means for Patients and Families
If you or a loved one has had pancreatitis linked to high triglycerides, or has been diagnosed with FCS:
- Know your numbers. Ask your doctor about your most recent triglyceride levels and your goal range.
- Talk with your care team about your current treatment plan, including diet, medications, and whether new options might be right for you.
- Ask about clinical trials. Research studies may offer access to emerging treatments.
- Stay informed. We'll share updates as this application moves through the FDA review process.
This article is for educational purposes only and is not medical advice. Always talk with your healthcare provider before making changes to your treatment.
Arrowhead Pharmaceuticals is a supporter of the National Pancreas Foundation. NPF does not endorse specific products or treatments.
.jpg)
.jpg)
.png)
